Proof of Concept (POC) in Patients With Ischaemic Stroke

PHASE2TerminatedINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

May 18, 2013

Primary Completion Date

July 28, 2014

Study Completion Date

July 28, 2014

Conditions
Cerebrovascular Accident
Interventions
DRUG

GSK249320 100/mg

Clear to opalescent, colorless to pale yellow or pale brown, and is supplied as a sterile, concentrated solution (1000mg/vial). GSK249320 is for IV use only.

DRUG

Placebo

Placebo is a clear, colorless solution (50mM acetate buffer, pH 5.5 containing 0.02% (w/v) polysorbate-80 and made isotonic with 111.2 mM sodium chloride). Placebo is for intravenous (IV) use only.

Trial Locations (36)

22417

GSK Investigational Site, Hamburg

22763

GSK Investigational Site, Hamburg

28177

GSK Investigational Site, Bremen

29223

GSK Investigational Site, Celle

30625

GSK Investigational Site, Hanover

32209

GSK Investigational Site, Jacksonville

37232

GSK Investigational Site, Nashville

40536

GSK Investigational Site, Lexington

45122

GSK Investigational Site, Essen

48149

GSK Investigational Site, Münster

49076

GSK Investigational Site, Osnabrück

61637

GSK Investigational Site, Peoria

79106

GSK Investigational Site, Freiburg im Breisgau

88048

GSK Investigational Site, Friedrichshafen

89081

GSK Investigational Site, Ulm

91054

GSK Investigational Site, Erlangen

97239

GSK Investigational Site, Portland

92868-4280

GSK Investigational Site, Orange

T6G 2B7

GSK Investigational Site, Edmonton

T6L 5X8

GSK Investigational Site, Edmonton

N6A 5A5

GSK Investigational Site, London

M4N 3M5

GSK Investigational Site, Toronto

J4V 2H1

GSK Investigational Site, Greenfield Park

J7Z 5T3

GSK Investigational Site, Saint-Jérôme

04103

GSK Investigational Site, Leipzig

CB2 0QQ

GSK Investigational Site, Cambridge

EX2 5DW

GSK Investigational Site, Exeter

G51 4TF

GSK Investigational Site, Glasgow

HA1 3UJ

GSK Investigational Site, Harrow

L7 8XP

GSK Investigational Site, Liverpool

SE5 9RS

GSK Investigational Site, London

SW17 0QT

GSK Investigational Site, London

NE1 4LP

GSK Investigational Site, Newcastle upon Tyne

RM7 0AG

GSK Investigational Site, Romford

M6 8HD

GSK Investigational Site, Salford

TQ2 7AA

GSK Investigational Site, Torquay

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01808261 - Proof of Concept (POC) in Patients With Ischaemic Stroke | Biotech Hunter | Biotech Hunter